Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced the presentation of updated efficacy and safety data from the Phase 3 long-term clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE